Girard Marc P, Fruth Uli, Kieny Marie-Paule
University Paris 7, UFR Biochemistry, 39 rue Seignemartin, 69008 Lyon, France.
Vaccine. 2005 Dec 30;23(50):5725-31. doi: 10.1016/j.vaccine.2005.07.045. Epub 2005 Aug 8.
Substantial progress has been made during the past 15 years towards the development of improved vaccines for tuberculosis. This is due to advances in the characterization of genes and antigens of Mycobacterium tuberculosis (M. tb), aided by the availability of genome sequences of different mycobacterial species and M. tb isolates and to greater understanding of protective immune responses to the pathogen in both animals and humans. More than one hundred candidate vaccines have been tested in animal models, representing all of the major vaccine design strategies, and some have now moved into clinical trials. This review summarizes recent advances in tuberculosis vaccine development.
在过去15年里,用于结核病的改良疫苗研发取得了重大进展。这得益于结核分枝杆菌(M. tb)基因和抗原特性鉴定方面的进展,不同分枝杆菌物种和M. tb分离株基因组序列的可得性起到了推动作用,同时也得益于对动物和人类针对该病原体的保护性免疫反应有了更深入的了解。已有一百多种候选疫苗在动物模型中进行了测试,涵盖了所有主要的疫苗设计策略,其中一些现已进入临床试验阶段。本综述总结了结核病疫苗研发的最新进展。